SAB Biotherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- SAB Biotherapeutics's estimated annual revenue is currently $6.9M per year.
- SAB Biotherapeutics's estimated revenue per employee is $100,500
- SAB Biotherapeutics's total funding is $40.4M.
Employee Data
- SAB Biotherapeutics has 69 Employees.
- SAB Biotherapeutics grew their employee count by 3% last year.
SAB Biotherapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer, EVP | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | Co-Founder and President | Reveal Email/Phone |
4 | VP Human Resources | Reveal Email/Phone |
5 | SVP Research and Development | Reveal Email/Phone |
6 | SVP, Research and Product Development | Reveal Email/Phone |
7 | VP, Clinical Operations | Reveal Email/Phone |
8 | Controller | Reveal Email/Phone |
9 | EVP & Chief Operating Officer | Reveal Email/Phone |
10 | Director | Reveal Email/Phone |
SAB Biotherapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is SAB Biotherapeutics?
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.
keywords:N/A
$40.4M
Total Funding
69
Number of Employees
$6.9M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
SAB Biotherapeutics News
That average rating earns SAB Biotherapeutics Inc an Analyst Ranking of 73, which means it ranks higher than 73 of stocks, based on data...
Sioux Falls-based SAB Biotherapeutics provided updates on its therapeutics for COVID-19, influenza and type 1 diabetes in reporting its...
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human...
SAB Biotherapeutics, a Sioux Falls, S.D.-based clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, closed a $14m Series B funding round. New investor, global healthcare leader Merck, known ...
SIOUX FALLS, S.D.–(BUSINESS WIRE)–January 7, 2020– SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into multiple collaboration and option agreements with global biotherapeutics leader ...
Other Companies in Sioux Falls
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.8M | 70 | -10% | N/A |
#2 | $13.2M | 70 | 21% | N/A |
#3 | $6.4M | 71 | 31% | N/A |
#4 | $7.5M | 72 | 20% | N/A |
#5 | $5.1M | 72 | -1% | N/A |